← Back to patent-cliff list
Leflunomide
Tier C — Watch / tradeLeflunomide
Sanofi
Originator
1998
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：DHODH
Brand：Arava, Repso
Indications (approved)：Rheumatoid arthritis, 狼疮肾炎, Psoriatic arthritis
Regional status
US
Approved
1998-09-10
EU
Approved
1999-09-02
China
Approved
2000-01-01
Japan
Approved
2003-04-16
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Leflunomide?
Approved indications include: Rheumatoid arthritis, 狼疮肾炎, Psoriatic arthritis.
When does the Leflunomide patent expire?
No public expiry year is available for Leflunomide yet; this page updates once verified.
How do I get a quote for Leflunomide intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-27